Skip to main content

Table 2 Individual patient estimates of amikacin pharmacokinetic parameters during treatment with CVVHDF, obtained from multiple amikacin serum concentrations in a dosage interval fitted to a one-compartment model

From: An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

ID k (h-1) CV%_k t1/2 (h) Vd (l) TBC (l h-1)
P1B 0.088 2.8 7.91 28.47 2.49
P2C 0.094 2.31 7.37 31.97 3.01
P3C 0.130 1.27 5.33 32.48 4.22
P4B 0.141 5.99 4.91 29.45 4.15
P5C 0.126 1.98 5.49 27.88 3.51
Mean +/− 0.116 +/−   6.21 30.05 3.48
s.d. 0.024   +/− +/− +/−
    1.34 2.07 0.74
Median 0.126   5.5 29.45 3.51
  1. t1/2: half life. Vd: volume of distribution. TBC: Total body clearance. k: elimination rate constant. CV%: coefficient of variation. PX (1–5) patients 1–5.